ADAP vs. ADMA, AUTL, INBX, VIR, FDMT, AMAM, FUSN, SRRK, TARS, and TWST
Should you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include ADMA Biologics (ADMA), Autolus Therapeutics (AUTL), Inhibrx (INBX), Vir Biotechnology (VIR), 4D Molecular Therapeutics (FDMT), Ambrx Biopharma (AMAM), Fusion Pharmaceuticals (FUSN), Scholar Rock (SRRK), Tarsus Pharmaceuticals (TARS), and Twist Bioscience (TWST). These companies are all part of the "biological products, except diagnostic" industry.
Adaptimmune Therapeutics (NASDAQ:ADAP) and ADMA Biologics (NASDAQ:ADMA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.
ADMA Biologics has higher revenue and earnings than Adaptimmune Therapeutics. ADMA Biologics is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.
ADMA Biologics has a net margin of -10.94% compared to Adaptimmune Therapeutics' net margin of -188.90%. ADMA Biologics' return on equity of 0.49% beat Adaptimmune Therapeutics' return on equity.
Adaptimmune Therapeutics presently has a consensus price target of $5.00, indicating a potential upside of 216.46%. ADMA Biologics has a consensus price target of $7.88, indicating a potential upside of 17.54%. Given Adaptimmune Therapeutics' higher possible upside, equities analysts plainly believe Adaptimmune Therapeutics is more favorable than ADMA Biologics.
Adaptimmune Therapeutics has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.
31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 18.1% of Adaptimmune Therapeutics shares are held by insiders. Comparatively, 6.0% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, ADMA Biologics had 5 more articles in the media than Adaptimmune Therapeutics. MarketBeat recorded 14 mentions for ADMA Biologics and 9 mentions for Adaptimmune Therapeutics. ADMA Biologics' average media sentiment score of 0.49 beat Adaptimmune Therapeutics' score of 0.36 indicating that ADMA Biologics is being referred to more favorably in the news media.
ADMA Biologics received 94 more outperform votes than Adaptimmune Therapeutics when rated by MarketBeat users. Likewise, 71.48% of users gave ADMA Biologics an outperform vote while only 62.53% of users gave Adaptimmune Therapeutics an outperform vote.
Summary
ADMA Biologics beats Adaptimmune Therapeutics on 14 of the 19 factors compared between the two stocks.
Get Adaptimmune Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Adaptimmune Therapeutics Competitors List
Related Companies and Tools